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ABSTRACT
Objective: Endometriosis affects up to 10% of women of reproductive age, and the main goal of
treatment is to relieve symptoms. Progestins have been the mainstay of endometriosis suppression, of
which dienogest has become an important option in many parts of the world. This is an expert
literature review, with recommendations on the use of dienogest in the context of various clinical
considerations when treating endometriosis.
Methods: A search of PubMed was conducted for papers published between 2007 and 2019 on the
use of dienogest in endometriosis. Experts reviewed these and included those they considered most
relevant in clinical practice, according to their own clinical experience.
Results: Evidence regarding the long-term use (>15months) of dienogest for the management of
endometriosis is presented, with experts concluding that the efficacy of dienogest should be assessed
primarily on its impact on pain and quality of life. Fertility preservation, the option to avoid or delay
surgery, and managing bleeding irregularities that can occur with this treatment are also considered.
Counseling women on potential bleeding risks before starting treatment may be helpful, and evidence
suggests that few women discontinue treatment for this reason, with the benefits of treatment
outweighing any impact of bleeding irregularities.
Conclusions: Overall, the evidence demonstrates that dienogest offers an effective and tolerable
alternative or adjunct to surgery and provides many advantages over combined hormonal
contraceptives for the treatment of endometriosis. It is important that treatment guidelines are
followed and care is tailored to the woman’s individual needs and desires.
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Introduction
Endometriosis is defined as the presence of endometrial-like
tissue outside the uterus1–3, causing inflammation and pain,
and resulting in scar tissue and adhesions3. However, the
exact prevalence is unknown owing to misdiagnosis,
diagnostic delay, and the asymptomatic nature of disease in
some cases2,4,5. Endometriosis is estimated to affect up to
10% of women of reproductive age5 and up to 50% of
women with subfertility6. Pain is considered to be the
defining symptom of endometriosis and can include
dysmenorrhea, noncyclic pelvic pain, and/or dyspareunia2,7.
Endometriosis can be both physically and emotionally
debilitating, thereby significantly reducing a woman’s quality
of life8–11.
Although there is substantial variation in the
recommendations and methodologic quality of the
guidelines for endometriosis, many guidelines agree that this
chronic condition requires long-term medical treatment
despite the availability of surgical management
options1,2,12–14. The management of symptoms is the
primary goal of treatment for endometriosis1,15. Thus,
diagnosis should be based on clinical symptoms, and
subsequent empirical treatment with hormonal treatments is
recommended for women with symptoms suspected to be
caused by endometriosis2,12. Progestins are recommended as
a first-line hormonal therapy for the treatment of
endometriosis-related pain and may compare favorably with
other treatment options16. Dienogest 2mg daily is a fourth-
generation progestin that first received approval for the
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treatment of endometriosis in the European Union in
200917–20. Dienogest binds to the progesterone receptor
and, when taken continuously, inhibits systemic
gonadotropin secretion and has local antiproliferative and
anti-inflammatory effects on endometriotic lesions17,21–23.
These antiproliferative and antiangiogenic properties of the
compound differentiate dienogest from other progestins in
the same class20,23.
Given the chronic nature of the condition, medical
treatments for endometriosis need to balance clinical efficacy
and symptom relief with an acceptable long-term safety
profile15. This paper provides an expert review of the
evidence for the use of dienogest in the long-term
management of endometriosis, including its efficacy, safety
profile, and use in the treatment of special patient
populations, with recommendations for consideration by
those in clinical practice.
Methods
This is a narrative review, for which separate PubMed
searches were conducted to retrieve publications on the use
of dienogest in endometriosis published between 2007 to
2019. Experts selected publications for inclusion based on a)
factors they considered relevant to the clinical management
of endometriosis, such as the efficacy and safety of
dienogest, and b) their own experiences in clinical practice.
Figure 1 presents the search terms used in each search
strategy and the number of citations resulting from these
(with removal of duplicate results).
Efficacy with long-term dienogest therapy for
endometriosis
There is no standard definition of “long-term” treatment for
endometriosis, and dienogest 2mg was approved on the
basis of the clinical development program, which included
studies lasting up to 15months24–28. Although there have
been few interventional studies since to investigate
treatment durations beyond 15months, supportive evidence
for long-term dienogest treatment is available from a
number of studies (Table 1)1–13. These studies show that
administration of dienogest for up to 5 years is effective in
preventing recurrence of disease and/or symptoms following
surgery, and reducing endometriosis-associated pain19,29–37.
A number of prospective, observational real-world studies
of long-term dienogest 2mg treatment in women with
endometriosis have been conducted, including VIPOS and
ENVISIOeN38,39. VIPOS was a post-approval study conducted in
six European countries, to evaluate the safety of dienogest
and other hormonal treatments for endometriosis. A total of
27,840 women were followed for up to 7 years (NCT01266421).
ENVISIOeN was a multicenter study assessing the effectiveness
of dienogest in improving quality of life in more than 800
women over 2 years (NCT02425462). Together, findings from
these large studies are expected to provide further insights
into the use of long-term treatment with dienogest 2mg.
Additionally, treatment with dienogest 2mg/day in 54
women for up to 24 months was associated with significant
improvements in physical, mental, social, emotional, and
general health parameters, compared with baseline values37.
Similarly, significant improvements in quality-of-life
categories were reported in women receiving a continuous
Search criteria: Visanne or contraceptives to prevent recurrence of lesions following 
surgery 
Search terms:  
(visanne OR dienogest) AND (endometriosis) AND (surgery OR surgical OR laparoscopy 
OR laparoscopic)   
Search results: 93
Search criteria: Management of endometriosis in adolescents 
Search terms:  
(visanne OR dienogest) AND (endometriosis) AND (adolescent OR teenager OR teenage 
OR ‘young adult’) (visanne OR dienogest) AND (endometriosis) AND (adolescent OR 
teenager OR teenage OR ‘young adult’) AND (management OR therapy OR treatment) 
Search results: 33
Search criteria: Contraceptive requirement with Visanne 
Search terms:  
(visanne OR dienogest) AND (endometriosis) AND (contraception OR contraceptive OR 
‘oral contraceptive’) (visanne OR dienogest) AND (endometriosis) AND (fertility OR 
pregnancy OR ovulation) 
Search results: 27
Search criteria: Endometriosis guidelines 
Search terms:  
(guidelines) AND (endometriosis) AND (management OR treatment OR therapy OR 
diagnosis) 
Search results: 216
Search criteria: Long term data for dienogest/Visanne - efficacy and safety 
Search terms:  
(visanne OR dienogest) AND (efficacy OR effective) AND (endometriosis)  
(visanne OR dienogest) AND (efficacy OR effective) AND (endometriosis) AND (‘long-
term’ OR ‘long term’)  
(visanne OR dienogest) AND (safety OR tolerability) AND (endometriosis)  
(visanne OR dienogest) AND (safety OR tolerability) AND (endometriosis) AND (‘long-
term’ OR ‘long term’)  
(visanne OR dienogest) AND (safety OR tolerability) AND (endometriosis) AND (‘bone 
mineral density’ OR ‘bone’ OR ‘bone metabolism’)  
(visanne OR dienogest) AND (safety OR tolerability) AND (endometriosis) AND 
(bleeding)  
(visanne OR dienogest) AND (safety OR tolerability) AND (endometriosis) AND 
(menstruation OR menses OR menstruate OR spotting) 
Search results: 141
Search criteria: Endometriosis and existing comorbidities 
Search terms:  
(visanne OR dienogest) AND (endometriosis) AND (myoma OR fibroid)  
(endometriosis) AND (‘myoma’ OR ‘fibroid’ OR ‘gynecological comorbidities’ OR 
‘gynecological co-morbidities’ OR ‘gynaecological comorbidities’ OR ‘gynaecological co-
morbidities’) 
Search results: 817
Search criteria: Management of bleeding irregularities in endometriosis 
Search terms:  
(visanne OR dienogest) AND (endometriosis) AND (management OR therapy OR 
treatment) AND (bleeding)  
(visanne OR dienogest) AND (endometriosis) AND (management OR therapy OR 
treatment) AND (menstruation OR menses OR menstruate) 
Search results: 41
Search criteria: Visanne and subtypes of endometriosis 
Search terms:  
(visanne OR dienogest) AND (endometriosis)  
(visanne OR dienogest) AND (‘deep infiltrating endometriosis’ OR ‘deep endometriosis’ 
OR ‘DIE’ OR ‘infiltrating endometriosis’) 
(visanne OR dienogest) AND (adenomyosis)  
(visanne OR dienogest) AND (‘endometrioma’ OR ‘ovarian endometrioma’ OR 
‘endometriotic cyst’) 
Search results: 189 
Search criteria: Visanne and oral contraceptives for the treatment of endometriosis 
Search terms:  
(‘endometriosis’) AND (‘combined oral contraceptive’ OR ‘oral contraceptives’ or 
‘contraceptives’ OR ‘contraception’ OR ‘birth control’) AND (‘treatment’ OR ‘therapy’ 
OR ‘management’) 
Search results: 803 
Figure 1. Search strategy for PubMed.
Note: Searches were conducted based on the listed terminology and following
additional terms (NOT ‘bladder’ and NOT ‘colorectal’) before combining and
filtering for relevant results.
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regimen of a combined oral contraceptive (COC) containing
dienogest 2mg/30lg ethinyl estradiol (n¼ 63), for up to
6months40. Significant improvements in sexual functioning
and monthly frequency of sexual intercourse were also seen
after treatment with dienogest 2mg/day, with improvements
in functioning seen as early as 6months after beginning
treatment37.
General safety profile with long-term dienogest therapy
for endometriosis
The general safety profile of dienogest indicates that it is
well tolerated in patients with endometriosis. In a pooled
analysis of four clinical trials, dienogest 2mg was well
tolerated, with a favorable safety profile extending for up to
65weeks. The most commonly reported adverse events were
headache, breast discomfort, depressed mood, and acne,
each occurring in <10% of patients, which were generally
mild to moderate in intensity and associated with low
discontinuation rates41. Administration of dienogest for up to
5 years has also demonstrated a favorable safety and
tolerability profile29–34.
Bone health
Maintenance of bone health is an important consideration
for the long-term management of endometriosis, particularly
in adolescents, given that treatments can involve
suppression of estrogen levels outside of the suggested
therapeutic window (20–60 pg/mL)34,42,43. Gonadotropin-
releasing hormone agonists, which are effective in the relief
of endometriosis-associated pain2, induce a hypoestrogenic
state, resulting in a 46% decrease in bone mineral
density (BMD) after 24 weeks of treatment, without add-
back therapy44,45. Similarly, the use of depot
medroxyprogesterone acetate is associated with loss of BMD,
although evidence suggests that BMD recovers following its
cessation46.
Treatment with dienogest 2mg has been associated with
moderate suppression of estrogen but with levels remaining
within the therapeutic window34,47. There is limited evidence
of the effect of dienogest 2mg on BMD in patients with
endometriosis, and small decreases of 0.5% to 2.7% BMD in
the lumbar spine after 1 year have been observed in
2075% of study populations24,30,48,49. Several studies have
reported changes in BMD (Table 2)24,30,48,49; however, it is
not well understood why some women experience BMD loss
and others do not. One study reported that loss in BMD is
largely thought to occur within the first 6months of
dienogest treatment, with some further decline up to 1 year,
followed by stabilization49. Following treatment cessation,
BMD levels have been shown to partially recover by
6 months after treatment24.
The clinical significance of the observed decreases in BMD
with dienogest 2mg in women with endometriosis remains
unclear, and may be due, at least in part, to the limitations
of BMD as a surrogate marker for osteoporosis, as it
addresses bone quantity rather than quality50. The National
Osteoporosis Foundation states that changes in bone density
are often smaller than the measurement error of most dual-
energy x-ray absorptiometry (DEXA) scanners51. The errors in
BMD measurement are well recognized and include
differences in reference populations and variations in
calculation methods that can all affect estimated T-score and
Z-score values. Despite attempts to standardize these values,
inconsistencies remain within and across BMD assessment
technologies that provide challenges in interpreting results.
As a consequence, many possible T-score and Z-score values
exist for any given BMD value, with significantly greater
variation in Z-scores, which are usually adjusted for
characteristics such as age, ethnicity, and occasionally size or
bone age52. In addition, according to the US Preventive
Services Task Force statement, 2 years may be the minimum
BMD screening interval necessary to detect possible bone
density loss due to the precision error of the methodology53.
Even longer intervals may be necessary to improve fracture
risk prediction53,54, as confirmed in a Canadian study55.
Similarly, the American College of Preventive Medicine
recommends that screening for osteoporosis should not
occur more often than every 2 years50. Thus, the BMD
screening intervals used in clinical trials may be too short to
detect the possible bone density loss that can result due
to treatment.
Data suggest that changes in BMD should not prevent
long-term use of dienogest in women with endometriosis.
However, further research is required in this area to address
outstanding questions, including whether there is an effect
of dienogest on BMD beyond the first year of treatment, and
the clinical significance of BMD reductions in premenopausal
patients, especially adolescent girls. International guidelines56
and recommendations given in the product label17 should
be consulted in the context of a woman’s overall bone
health. Osteoporosis risk factors should be considered, and
health factors, such as intake of calcium or vitamin D for
general bone health, should be discussed with patients
(although currently there is no evidence to suggest
additional monitoring or supplements are required with
dienogest treatment)17. In addition, the clinical significance
of BMD findings must be considered in the context of the
well-known limitations of BMD assessment.
Breast health
Women with endometriosis may be concerned about a
potential increased cancer risk with hormonal treatments57.
Although evidence for the clinical effects of dienogest on
breast tissue is limited, no serious adverse events related to
breast disorders were reported in the clinical development
program41. Breast discomfort was the most frequently
reported breast-related adverse event considered to be
possibly treatment related in clinical trials17,41. A pilot study
investigating the impact of high-dose dienogest (20mg daily
for 24weeks) on breast tissue in women with endometriosis,
identified no adverse effects on the breast gland, fat layer
thickness at the areola edge, or duct diameter58.
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The relationship between COCs and progestins with
breast cancer has been controversial and mainly based on
population-based epidemiologic studies59–62. The risk of
breast cancer was shown to be similar between different
COCs, and findings for different progestin-only formulations
were inconsistent57. Furthermore, in a mouse model,
dienogest demonstrated potent anticancer activity against
hormone-dependent cancers in two cell lines derived from
human endometrial carcinoma, and one cell line derived
from human breast carcinoma, where other progestins
showed either no response or were only effective at a higher
dose than that of dienogest63. It has also been
demonstrated that dienogest exhibits antiangiogenic activity,
which suggests that, in animal models, it may have
antitumor effects on human hormone-dependent cancer
xenografts, such as endometrial and breast cancers64. In
summary, there is no direct evidence indicating an
additional risk of breast cancer with dienogest treatment in
humans, but the risk is likely to be similar to that of
other progestins.
Expert recommendations
 Long-term treatment of endometriosis with dienogest
2mg (>15 months) should continue for as long as
needed by the individual woman (e.g. until pregnancy is
desired, disease recurs, or side effects occur), based on
local treatment labels
 The efficacy of dienogest 2mg should be measured
primarily by its impact on pain and quality of life for
the woman
 Other important considerations are effects of medical
management on menstrual bleeding, reduction of
lesion size, preservation of fertility, and the ability to
avoid or delay surgery
 Small decreases in BMD have been seen with dienogest
treatment of up to 52 weeks; however, there does not
appear to be a cumulative decrease in BMD, and there is
evidence of partial recovery in BMD following treatment
cessation24,48
 The clinical significance of the decreases in BMD observed
with dienogest treatment are currently unknown
 There is no evidence suggesting the need for
additional monitoring or supplements for bone health
with dienogest treatment
 There is no evidence to suggest an increased risk of
fracture in later life
 Changes in BMD should not prevent long-term
treatment with dienogest, but patients should be
advised about the risks of decreased BMD, particularly
if already predisposed to osteoporosis due to factors
including chronic steroid use, previous fragility
fractures, smoking, and malabsorption conditions, such
as inflammatory bowel disease
 Lifestyle modifications should be discussed with
patients, with suggestions including (a) calcium and
vitamin D supplementation, (b) weight-bearingTa
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exercise, (c) smoking cessation, and (d) avoidance of
excessive alcohol use
 In terms of cancer risk, women receiving dienogest do
not need to be treated or monitored differently from
other women. Women should be offered appropriate
counseling and time to ask questions. Ovarian masses
should be monitored and treated according to published
clinical practice guidelines, which aim to minimize
morbidity with conservative management, laparoscopic
techniques, and appropriate referral65.
Comparison of combined oral contraceptives
and dienogest
Combined hormonal contraceptives, including COCs, are
relatively inexpensive, with a well-established safety profile.
Although there is some evidence that COCs can be effective
in relieving dysmenorrhea, the off-label use of COCs in the
treatment of endometriosis has been largely based on data
from uncontrolled trials16,66,67. Therefore, there remains a
lack of solid clinical trial evidence supporting the efficacy of
COCs in alleviating the symptoms of endometriosis, such as
pain16,68. A recent Cochrane review concluded that, based
on the limited evidence and high risk of bias, there is
insufficient support to judge the effectiveness of COCs alone
compared with placebo, or combined with other medical
treatments68. In addition, the rationale for the use of COCs
has been questioned, in that they provide a higher than
physiologic dose of estrogen that maintains the existing
estrogen–progesterone disequilibrium, and may stimulate
the disease69. Furthermore, medical contraindications limit
the use of COCs in clinical practice16. The use of oral
contraceptives (OCs) has also been studied, indicating the
association between past use of OCs for severe primary
dysmenorrhea and surgical confirmation of endometriosis,
particularly of deep-infiltrating endometriosis (DIE)70.
Conversely, as described in a meta-analysis, no such
association is apparent between current OC use and
endometriosis, a result found in agreement with a
meta-analysis71.
As a consequence, some experts have suggested that
progestins be used as first-line medical treatment for
endometriosis16,69. Some clinical practice guidelines also
recommend progestins as first-line therapy2,13.
Unlike COCs, dienogest 2mg has not been developed as
a contraceptive, and barrier contraception is recommended
during treatment to prevent pregnancy, although ovulation
inhibition was demonstrated in early clinical trials17,72.
Numerous studies have shown that progestin-releasing
intrauterine systems or implants improve pelvic pain,
dysmenorrhea, and quality of life in women with surgically
confirmed endometriosis66,73.
Expert recommendations
 Data support the efficacy of COCs in reducing
dysmenorrhea in women with endometriosis but not the
relief of other typical pain symptoms (e.g. dyspareunia,
non-cyclic pelvic pain)
 COCs containing estrogen (ethinylestradiol or
estradiol) and progestin components have additional
contraindications and side effects compared with
progestin-only products, such as dienogest16. A history
of OC use for dysmenorrhea is associated with diagnosis
of endometriosis, particularly of DIE, later in life70
 The rationale and evidence for OCs in the treatment
of endometriosis are limited. Progestins (including
dienogest) may be a better first-line treatment option
with fewer contraindications compared with COCs16
 Evidence supports the efficacy of dienogest 2mg in
reducing multiple types of endometriosis-associated pain,
including pelvic pain, dysmenorrhea, dyspareunia, dysuria,
and dyschezia
 The role of dienogest 2mg in the management of fertility
requires further investigation
Management of bleeding irregularities
Treatment with dienogest 2mg, as with other progestins,
leads to endometrial regression and bleeding irregularities22.
Initial bleeding during the first few months can be
consistent, typically lasting for 8–10 days, with decreases in
intensity and frequency over time28,41,47,74. In addition,
spotting can occur with long-term dienogest treatment17.
Although the potential impact of bleeding irregularities on
patient acceptance and compliance with dienogest 2mg is a
recognized challenge, <1% of patients in clinical trials
discontinued treatment for this reason41,74. However, given
that irregular bleeding patterns in the first 3months of
treatment are thought to occur in 20% of patients, it is
recommended that patients be counseled to prepare and
reassure them of possible bleeding41. Regular follow-up and
support at this time are also advised.
Abnormal uterine bleeding may require further
investigation via transvaginal ultrasound examination and
physical and laboratory assessment, including recording
sexual history and screening for sexually transmitted
infections, such as chlamydia, when applicable75,76.
Expert recommendations
 Before treatment initiation, patients should be counseled
on what to expect regarding bleeding pattern changes
 Women should be reassured that bleeding with
dienogest 2mg is not a sign of a lack of efficacy or
recurrence of disease
 Two distinct types of bleeding irregularities may occur
during dienogest 2mg treatment: initial bleeding
during the first few months, and bleeding/spotting
with longer-term use
 Initial bleeding can be consistent and typically lasts
for 8–10 days. A regimen involving treatment with a
gonadotropin-releasing hormone followed by long-term
dienogest therapy may reduce initial irregular
bleeding77. Furthermore, initiation of dienogest 2mg at
the onset of menses may also decrease initial bleeding
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 Bleeding that occurs during long-term treatment is
typically spotting. If the sonographic endometrium
thickness is low, management can include a treatment
break of 5–7 days to allow for the recovery of the
atrophy of the endometrium, or a short-term application
of 1mg oral or transdermal estradiol (5–7 days)
 The occurrence of abnormal uterine bleeding may require
further investigation, such as by ultrasound examination
 Persistence of abnormal uterine bleeding should
prompt further investigations for other uterine
pathologies beyond endometriosis
 Recording sexual history and screening for sexually
transmitted infections may be advised
Preventing postsurgical recurrence of endometriosis
Endometriosis is a chronic disease requiring long-term
management, with the goal of maximizing the use of
medical treatment and avoiding repeated surgical
procedures78. Even after successful surgery, recurrence of
endometriosis-associated symptoms is frequently
observed79,80, and prescription of medical treatment for the
long-term prevention of recurrence is recommended2.
Several studies support the use of long-term dienogest for
the prevention of recurrence29,30,33,81–87, and a reduction in
recurrent endometrioma size30 has been observed for up to
5 years following surgery (Table 3)29,30,33,81–85. In a
retrospective cohort study of 568 women with
endometrioma, cumulative disease recurrence rates 5 years
postsurgery were 69% in women receiving no medical
treatment, compared with 4% in women taking dienogest
2mg81. Additionally, in a retrospective review, 55.5% of
women who discontinued treatment with OCs experienced
postoperative recurrence of ovarian endometriomas,
compared with a rate of 0% in those who received
continuous treatment with dienogest82. In contrast, evidence
to suggest the efficacy of COC regimens in the reduction of
postsurgical recurrence is limited16,88.
Expert recommendations
 Asymptomatic ovarian endometriomas should be
monitored but do not require medical or surgical
treatment; if the endometrioma is large and there is a risk
of rupture, then surgery should be considered
 Surgery should be considered in cases of atypical findings
via ultrasound examination
 Painful ovarian cysts >3–4 cm in diameter should be
treated surgically, in line with treatment guidelines2
 Medical treatments can be prescribed for symptomatic
relief when awaiting surgery
 Medical treatments, including dienogest 2mg, should be
prescribed postsurgery to prevent the recurrence of
endometriosis, unless there is an immediate desire for
pregnancy. Postoperative dienogest 2mg treatment has
been effective in the prevention of endometriosis
symptom recurrence and endometrioma29,30,33,81–86
 Long-term treatment with dienogest 2mg has been
shown to decrease recurrent endometrioma size, which
may indicate an additional benefit of its use in medical
treatment30
Treating complex patients
The available evidence indicates a role for dienogest 2mg in
the management of adenomyosis, DIE, and endometrioma.
Adenomyosis
Adenomyosis is an estrogen-dependent disease that is
characterized by the growth of ectopic endometrial-like
tissue within the myometrium of the uterus, and studies
have reported a prevalence of approximately 2243% in
women with endometriosis89–91. Conservative surgical
procedures in the treatment of adenomyosis are associated
with a high rate of recurrence in the long-term (3849%
2–3 years after the procedure); however, evidence indicates
that concurrent medical treatment can reduce this
recurrence rate92–95. In addition, the risk of bleeding with
surgical procedures is high, owing to the proximity of the
myometrial surface to significant arteries94.
Guidelines recommend that a levonorgestrel-releasing
intrauterine device (LNG-IUD) should be considered initially
in women with fibroids <3 cm in diameter96. Where an
alternative treatment is preferred by the woman or is
necessary, evidence suggests that dienogest is effective and
Table 3. Data supporting the efficacy of dienogest for the prevention of postsurgical recurrence.
Study Duration of dienogest administration Duration of follow-up Ovarian recurrence Pain symptoms
Takaesu et al.85 6 months 24 months 4/54 N/A
Park et al.30 17 (1232) months 18 months 1/114 Pain improvement in 72.6%
of patients
Ouchi et al.82 13.28 ± 4.85 months 13.3 ± 4.9 months 0/7 N/A
Lee et al.29 72.2 ± 5.2 weeks
(range, 48164)
41 months 9/514 Pain improvement in 82.2% of
patients (61.6% “improved”; 20.6%
“much improved”)
Chandra et al.33 12.0 ± 7.1 months
(range, 635)
30.2 ± 20.9 months 3/203 N/A
Adachi et al.83 636 months 24 months 0/40 Improved
Ota et al.81 – 61.2 ± 1.1 months 4/151 N/A
Yamanaka et al.84 31 ± 17.6 months 35 ± 17.6 months 3/59 Endometriosis-related symptoms after
operation (VAS >4) 4/59 (6.7%)
Total 636 months 1361 months 24/1142 (2.1%)
Abbreviations. N/A, not available; VAS, visual analog scale.
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well tolerated in the treatment of painful symptoms in
patients with this condition89. In a phase III randomized trial
of women with adenomyosis (n¼ 67), treatment with
dienogest was associated with a significant decrease in visual
analog scale scores versus placebo (58.4 ± 23.6mm vs.
20.6 ± 23.6mm, p< .001)89. It is recommended that
physicians monitor patients, particularly those of a younger
age, for anemia17,97. In the long term, the use of medical
management is preferred for the treatment of adenomyosis,
thus avoiding surgery and allowing patients to conceive
if desired98.
Deep-infiltrating endometriosis
DIE is a severe form of endometriosis that occurs when
the peritoneal surface is invaded and areas surrounding the
uterus are affected. DIE lesions often extend >5mm into the
peritoneum and the depth of infiltration is often related to
the type and severity of symptoms99–101. DIE is associated
with high levels of pelvic pain, as well as infertility,
dysmenorrhea, and dyspareunia102. Evidence suggests that
dienogest is effective in the management of DIE84,103.
Treatment with dienogest 2mg for up to 12months in
women with DIE was associated with reductions in a number
of endometriosis-associated pain symptoms, including
dysmenorrhea, pelvic pain, dyspareunia, and bowel/intestinal
pain103,104. In a single small study, postsurgical dienogest
2mg treatment was associated with a reduced occurrence of
endometriosis-associated pain compared with no medical
treatment84. Surgery should be considered in cases that are
complicated by urethra, bowel, or kidney obstruction, or
fistulae in rectovaginal endometriosis because the risk of
complications is high2.
Comorbidities in patients with endometriosis
The symptoms of endometriosis frequently affect
psychologic and social functioning, significantly
compromising patients’ relationships, sexuality, and mental
health105,106. Furthermore, women who suffer from
endometriosis report high levels of anxiety, depression, and
other psychiatric disorders, which may amplify the severity of
pain105. Psychologic issues should be considered by
healthcare professionals and openly discussed with patients
before initiation of hormonal treatments for
endometriosis105. Depressed mood can be observed with
dienogest 2mg as with other hormonal treatments,
occurring in <10% of women in a pooled analysis of safety
data from pivotal dienogest studies41. Patients should be
advised that mood changes or depression are a possible
result of all progestins, not specifically dienogest, and they
should be watchful for any changes that may occur.
Studies have also suggested that endometriosis may be
associated with irritable bowel syndrome (IBS), with a five
times greater prevalence of IBS observed in women with
endometriosis compared with those without
endometriosis107. Additionally, adolescent patients with
endometriosis may be more likely to report migraines than
those without, with nearly five-fold greater odds of
migraines reported among those with endometriosis,
compared with those without108.
Expert recommendations
 The use of medical treatments should be maximized for
patients with adenomyosis
 Dienogest 2mg treatment effectively reduces pain for
patients with adenomyosis and may be an alternative
treatment to LNG-IUD
 Patients with symptomatic DIE can be managed with
dienogest 2mg
 Where extragenital endometriosis results in urethra,
bowel, or kidney obstruction, or fistulae in rectovaginal
endometriosis, surgical treatment options should
be considered
 Management of mood disturbances and depression with
dienogest 2mg should include regular monitoring during
routine follow-up appointments and may require
additional steps for women with a history of depression
 Patients should be made aware that depression and
mood disturbances can occur with dienogest 2mg
treatment, as with all hormonal therapies
 As part of routine follow-up during treatment, patients
should be monitored for signs of depression or mood
disturbances
 Possible introduction of a “treatment break” might be
warranted in the context of long-term treatment for
patients with mood symptoms
 If women have a history or current diagnosis of clinical
depression, care should be taken in the prescription of
dienogest 2mg or other hormonal treatments. In
addition, the involvement of a mental-health specialist
may be warranted
Diagnosis and management of endometriosis in
adolescent patients
Endometriosis affects a significant proportion of adolescent
girls, but diagnostic delays are common in this
population109,110, partially due to the differences in clinical
presentation compared with adults. These delays can partly
explain the severity of disease affecting these younger
patients and support the need for a simple, noninvasive tool
for the screening of endometriosis in this population110. It is
important that physicians recognize endometriosis in
younger patients so timely treatment can be given109. As
such, patients presenting with dysmenorrhea and chronic
pelvic pain should not be underestimated, and a detailed
and accurate history should be obtained before performing
clinical evaluation and pelvic sonography111. Furthermore, in
adolescent patients, the focus should be on clinical rather
than surgical/laparoscopic diagnosis. Receiving a diagnosis of
endometriosis can provide some reassurance to adolescent
patients regarding the cause of their pain, but it can also
cause anxiety upon learning that it may require long-term
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treatment and surgery, and may cause infertility; therefore,
scheduling frequent follow-up visits is important.
Current surgical treatment options have potential
deleterious effects on the ovarian follicle reserve, and some
studies have suggested a recurrence rate of up to 56% in
adolescent patients with endometriosis110. As it stands, a
conservative treatment approach, avoiding surgery, is
desirable, and hormonal therapies and analgesics are
recommended for relief of endometriosis-related pain2. In a
52-week, multicenter study of adolescent patients, dienogest
2mg was effective in relieving the symptoms (pelvic pain,
dysmenorrhea, and dyspareunia) and signs (pelvic tenderness
and induration) of endometriosis. In addition, dienogest 2mg
was generally well tolerated, consistent with findings
previously reported in adults with endometriosis24. Given
that adolescence is a crucial time for accumulation of BMD,
data on the impact of endometriosis treatment at this age
are of particular interest24. In adolescents treated with
dienogest 2mg for 1 year, a 1.2% reduction in BMD from
baseline to the end of treatment was observed24. This slight
reduction should be balanced against recovery of BMD once
treatment is stopped, and the significant reductions in
endometriosis-associated pain observed with treatment24.
The impact of these observations in adolescent patients
must also be considered in context with the fact that BMD is
only a surrogate marker for bone health50,112. Important
confounding factors should be considered when performing
DEXA, especially in children and adolescent patients,
including variations in age, race, gender, pubertal status, and
height. Thus, errors in interpretation of bone densitometry in
children and adolescents can lead to significant
overdiagnosis of osteopenia, or even osteoporosis, on the
basis of low BMD scores inferred from DEXA112.
In conclusion, although challenges with the interpretation of
BMD in the adolescent population must be recognized,
dienogest 2mg may be favorable owing to the lack of alternative
treatments when the benefit–risk profile is considered.
Expert recommendations
 The occurrence of endometriosis and the impact of
symptoms should not be underestimated in adolescent
patients, to ensure timely diagnosis and
treatment initiation
 In adolescent patients, surgical diagnosis of endometriosis
should be avoided in favor of clinical diagnosis based
on symptoms
 For adolescent patients with endometriosis, multiple
treatment options are available and the use of dienogest
2mg has been investigated in this patient population.
However, treatment decisions should be made on an
individual basis, using a risk–benefit approach that
considers efficacy and safety
Conclusions
Endometriosis is a chronic disease and, as such, medical
treatment should be maximized and surgical interventions
avoided and minimized, unless necessary. Dienogest 2mg
offers an effective and tolerable alternative to surgical
intervention for the long-term management of
endometriosis, providing several important advantages over
COCs. Furthermore, the evidence highlights that patients are
willing to accept the bleeding irregularities that often occur
with dienogest 2mg, given the pain relief experienced. In
clinical practice, counseling patients regarding the expected
side effects, weighing up the efficacy and safety of each
treatment approach, and following treatment guidelines to
provide tailored care according to each woman’s needs and
desires, are all important components of management.
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